Literature DB >> 16107495

Predictors of discontinuation of benzodiazepine prescription after sending a letter to long-term benzodiazepine users in family practice.

W J M J Gorgels1, R C Oude Voshaar, A J J Mol, E H van de Lisdonk, A J L M van Balkom, M H M Breteler, H J M van den Hoogen, J Mulder, F G Zitman.   

Abstract

BACKGROUND: Predictors of benzodiazepine discontinuation after sending a discontinuation letter by the family practitioner have not been established sufficiently.
OBJECTIVE: To identify predictors of short- and long-term discontinuation of benzodiazepine use and relapse in use after a minimal intervention with a discontinuation letter followed by an offer for an evaluation consultation.
METHODS: Predictors of benzodiazepine discontinuation and relapse in use were studied by logistic regression analysis and survival analysis within a family practice population of long-term benzodiazepine users (n = 1707) addressed by a discontinuation letter and followed for 21 months.
RESULTS: A lower baseline prescription, a shorter duration of use, male gender and use of an agent with a half-life time <24 hours were predictive of complete discontinuation in the short (6 months) and long term (21 months). Multiple agent use at baseline, use of antidepressants at 6 months and benzodiazepine type (anxiolytic/hypnotic) at baseline predicted relapse. Attendance at an evaluation consultation 3 months after the letter was sent was not predictive of discontinuation or relapse.
CONCLUSIONS: Amount of baseline use and duration of use are the main determinative characteristics of successful discontinuation. The discontinuation letter intervention is suitable for use with a broad group of long-term benzodiazepine users in family practice and can be used as a first step within a stepped care approach to decrease long-term benzodiazepine use.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16107495     DOI: 10.1093/fampra/cmi065

Source DB:  PubMed          Journal:  Fam Pract        ISSN: 0263-2136            Impact factor:   2.267


  7 in total

1. 

Authors:  Kevin Pottie; Wade Thompson; Simon Davies; Jean Grenier; Cheryl A Sadowski; Vivian Welch; Anne Holbrook; Cynthia Boyd; Robert Swenson; Andy Ma; Barbara Farrell
Journal:  Can Fam Physician       Date:  2018-05       Impact factor: 3.275

Review 2.  A Systematic Review of Opioid and Benzodiazepine Misuse in Older Adults.

Authors:  Rachel D Maree; Zachary A Marcum; Ester Saghafi; Debra K Weiner; Jordan F Karp
Journal:  Am J Geriatr Psychiatry       Date:  2016-06-07       Impact factor: 4.105

3.  Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline.

Authors:  Kevin Pottie; Wade Thompson; Simon Davies; Jean Grenier; Cheryl A Sadowski; Vivian Welch; Anne Holbrook; Cynthia Boyd; Robert Swenson; Andy Ma; Barbara Farrell
Journal:  Can Fam Physician       Date:  2018-05       Impact factor: 3.275

4.  Benzodiazepine use in the real world of psychiatric practice: low-dose, long-term drug taking and low rates of treatment discontinuation.

Authors:  Antonio Veronese; Massimo Garatti; Andrea Cipriani; Corrado Barbui
Journal:  Eur J Clin Pharmacol       Date:  2007-07-10       Impact factor: 2.953

Review 5.  Withdrawing benzodiazepines in primary care.

Authors:  Malcolm Lader; Andre Tylee; John Donoghue
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

6.  Characteristics of patients who were able to switch from benzodiazepine hypnotics to lemborexant.

Authors:  Hidenobu Suzuki; Hiroyuki Hibino
Journal:  SAGE Open Med       Date:  2021-08-04

7.  An educational intervention to reduce the use of potentially inappropriate medications among older adults (EMPOWER study): protocol for a cluster randomized trial.

Authors:  Philippe Martin; Robyn Tamblyn; Sara Ahmed; Cara Tannenbaum
Journal:  Trials       Date:  2013-03-20       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.